Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotechnology pioneer advancing DARPin therapeutics for oncology and radiopharmaceutical applications. This page provides investors and industry observers with official company announcements, clinical trial milestones, and strategic partnership updates.
Access the latest developments in MOLN's Radio-DARPin Therapy platform, Switch-DARPin candidates, and ophthalmology programs. Our curated news collection enables efficient tracking of regulatory filings, preclinical data disclosures, and financial results without promotional commentary.
Key content categories include clinical trial progress, collaborative research updates with partners like Orano Med, and technology platform innovations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for centralized access to Molecular Partners' verified announcements. For comprehensive analysis of MOLN stock performance, visit Stock Titan's dedicated market data section.
Molecular Partners (NASDAQ: MOLN) presented three significant developments at AACR 2025:
- Positive IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer, with clinical development starting in 2025
- Initial preclinical data on a new mesothelin-targeting Radio-DARPin for solid tumors
- Preclinical proof-of-concept data for a logic-gated CD3 Switch-DARPin T cell engager
The MP0712 program showed high tumor uptake and favorable safety profiles in mouse models. The mesothelin-targeting Radio-DARPin demonstrated strong tumor accumulation while avoiding interference from shed mesothelin. The Switch-DARPin technology showed specific T cell activation in the presence of target cells and achieved tumor regression in mice without peripheral T cell activation.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) held its Annual General Meeting where shareholders approved all Board proposals by a wide majority. The company, which develops DARPin therapeutics, reported a significant net loss of CHF 50.6 million for 2024, increasing the total loss carried forward to CHF 199.4 million.
Shareholders approved the annual review, financial statements, and compensation report. All Board members were re-elected for one-year terms, with William Burns re-elected as Chairman and reappointed as chair of the Nomination and Compensation Committee. KPMG AG Zurich was re-elected as statutory auditors for 2025, and Anwaltskanzlei Keller AG was chosen as independent proxy until 2026.
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) has announced three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago.
The presentations will showcase:
- MP0712, a Radio-DARPin targeting DLL3 labeled with 212Pb for small cell lung cancer treatment, co-developed with Orano Med, entering First-in-Human studies in 2025
- Initial preclinical data on a second 212Pb-based Radio-DARPin targeting mesothelin (MSLN) in solid tumors, also co-developed with Orano Med
- Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation for solid tumors
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company specializing in DARPin therapeutics, has announced its upcoming Annual General Meeting for 2025. The meeting is scheduled for Wednesday, April 16, 2025, at 9:00 CET, with doors opening at 8:30 CET. The event will take place at JED Events in Schlieren, Switzerland.
Molecular Partners (MOLN) reported its Q4 2024 and full-year financial results, highlighting significant progress in its DARPin therapeutics pipeline. The company ended 2024 with CHF 149.4 million in cash and equivalents, expected to support operations into 2027.
Key developments include:
- Radio-DARPin MP0712 targeting DLL3 to enter first human trials in 2025
- Strategic partnership with Orano Med expanded to ten Radio-DARPin programs
- MP0533 Phase 1/2a clinical trial showing improved response rates
- Total revenues of CHF 5.0 million in 2024 (down from CHF 7.0 million in 2023)
- Net loss of CHF 54.0 million (improved from CHF 62.0 million in 2023)
- Operating expenses of CHF 66.2 million (reduced from CHF 68.1 million in 2023)
The company raised approximately $20 million in October 2024 from investors including HBM Partners, focusing on radiopharmaceutical pipeline development.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing DARPin therapeutics, has announced its participation in key investor conferences and its upcoming financial results presentation.
The company will participate in two major healthcare conferences: the TD Cowen 44th Annual Health Care Conference in Boston (March 3-5, 2025) and the Leerink Partners Global Healthcare Conference 2025 in Miami (March 10-12, 2025). CEO Patrick Amstutz and CMO Dr. Philippe Legenne will conduct fireside chats at both events.
The company will host its Full Year 2024 Financial Results Conference Call on March 7, 2025, at 8:00 am ET (2:00 pm CET), following the publication of its Annual Report on March 6.
Molecular Partners (NASDAQ: MOLN) has outlined its clinical expansion plans for 2025, highlighting key developments in its Radio-DARPin and Switch-DARPin programs. The company's Radio-DARPin MP0712, targeting DLL3, will enter first-in-human studies in 2025, while Mesothelin has been selected as the second target in their Radio-DARPin pipeline. Both programs are being co-developed with Orano Med, with their partnership now expanded to 10 programs.
The company reported encouraging results from MP0533's clinical trials, with improved response rates in cohort 8 using more frequent dosing. As of December 31, 2024, the company maintains a strong financial position with CHF 149 million in cash and cash equivalents.
The CD3 Switch-DARPin platform has demonstrated proof-of-concept in solid tumors, showing conditional T cell activation and CD2 co-stimulation, with further data expected in Q2 2025. The company plans to submit an IND application for MP0712 in H1 2025.
Molecular Partners (MOLN) and Orano Med have expanded their strategic collaboration in targeted alpha radio-therapies for cancer, increasing their joint programs from four to ten. The partnership combines Molecular Partners' Radio-DARPin Platform with Orano Med's 212Pb supply and development capabilities.
Under the new agreement, Molecular Partners will lead the development of six additional programs with a royalty arrangement. Orano Med has the option to move two of these programs into 50/50 co-development with commercialization rights. The most advanced program, MP0712, a DLL3-targeted radio-DARPin, is expected to begin human trials in 2025.
The initial agreement from January 2024 covered four programs with equally shared costs and profits. Molecular Partners holds commercialization rights for MP0712 and a second mesothelin-targeting program, while Orano Med has rights to programs three and four. Financial terms weren't disclosed, and MOLN maintains its funding guidance into 2027.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company specializing in DARPin therapeutics, has announced its participation in two major investor conferences in January. Chief Operating Officer Alexander Zürcher will present at the Baader Helvea Swiss Equities Conference on January 8 in Bad Ragaz, Switzerland. Subsequently, CEO Patrick Amstutz will present at the 43rd Annual JP Morgan Healthcare Conference on January 15 at 9:00am PT in San Francisco. The presentations will showcase the company's latest developments and outlook for 2025, with webcasts available on the Molecular Partners website.
Molecular Partners (NASDAQ: MOLN) presented data from two programs at ASH 2024: MP0533 phase 1/2a study and preclinical data on MP0621. The MP0533 study, targeting relapsed/refractory AML or MDS/AML, showed an acceptable safety profile in 37 patients across seven cohorts, with initial antileukemic and pharmacodynamic activity. Despite lower than anticipated drug exposure, four responders were reported. The company is amending the protocol to optimize dosing schedules.
The preclinical data for MP0621, a Switch-DARPin candidate for hematopoietic stem cell transplantation conditioning, demonstrated its intended mechanism of HSC depletion while reducing off-target effects. However, non-human primate data doesn't support its use in AML patients as previously hypothesized. The company is now evaluating MP0621 for partnering opportunities.
FAQ
What is the current stock price of MOLECULAR PARTNERS (MOLN)?
What is the market cap of MOLECULAR PARTNERS (MOLN)?
